Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
The study aimed to present our experience in treating recurrent HCV genotype 4 infection post
living donor liver transplantation (LDLT) since introduction of the second generation direct
acting antiviral drugs (DAAs) in Egypt.